Progesterone receptor modulators in gynaecological practice
This review examines progesterone receptor modulators (PRMs), detailing their discovery based on an unexpected antiproliferative effect on the endometrium and their current applications in gynecology.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (100)
- Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy via openalex
- Clinical utility of progesterone receptor modulators and their effect on the endometrium via openalex
- Daily Low-Dose Mifepristone Has Contraceptive Potential by Suppressing Ovulation and Menstruation: A Double-Blind Randomized Control Trial of 2 and 5 mg per Day for 120 Days via openalex
- Effect of long-term treatment with low-dose mifepristone on the endometrium via openalex
- Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study via openalex
- Mifepristone. Auxiliary therapeutic use in cancer and related disorders. via openalex
- Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU 486 via openalex
- Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis via openalex
- Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications via openalex
- Selective Progesterone Receptor Modulators (SPRMs) via openalex
- Selective progesterone receptor modulators (SPRMs) : a novel therapeutic concept in endometriosis via openalex
- The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women via openalex
- W1984592479 via openalex
- W1986178398 via openalex
- W2003122228 via openalex
- W2005566479 via openalex
- W2007801308 via openalex
- W2007951223 via openalex
- W2011947490 via openalex
- W2013955786 via openalex
- W2014208190 via openalex
- W2016430694 via openalex
- W2024438898 via openalex
- W2026392453 via openalex
- W2026781892 via openalex
- W2028520025 via openalex
- W2030386607 via openalex
- W2032677173 via openalex
- W2035366757 via openalex
- W2039274017 via openalex
- W2039633328 via openalex
- W2044060855 via openalex
- W2045524208 via openalex
- W2047203443 via openalex
- W2047372977 via openalex
- W2048489461 via openalex
- W2048957217 via openalex
- W2051109327 via openalex
- W2054254905 via openalex
- W2057430669 via openalex
- W2063169494 via openalex
- W2064203976 via openalex
- W2064960854 via openalex
- W2069392551 via openalex
- W2073187669 via openalex
- W2078370543 via openalex
- W2079241337 via openalex
- W2079594782 via openalex
- W2080225961 via openalex
- W2080880856 via openalex
- W2082030213 via openalex
- W2086872954 via openalex
- W2088537209 via openalex
- W2090345475 via openalex
- W2097240287 via openalex
- W2098019331 via openalex
- W2102218899 via openalex
- W2102395114 via openalex
- W2103171543 via openalex
- W2105882735 via openalex
- W2108010472 via openalex
- W2113190292 via openalex
- W2115429362 via openalex
- W2120423870 via openalex
- W2122146138 via openalex
- W2128954873 via openalex
- W2134535954 via openalex
- W2138101788 via openalex
- W2138981182 via openalex
- W2142020314 via openalex
- W2148466832 via openalex
- W2148686723 via openalex
- W2154673098 via openalex
- W2155493571 via openalex
- W2155524358 via openalex
- W2165639852 via openalex
- W2171549981 via openalex
- W2200093255 via openalex
- W2204640292 via openalex
- W20996512 via openalex
- W2401405773 via openalex
- W2401675985 via openalex
- W2403970471 via openalex
- W2587790761 via openalex
- W3134240173 via openalex
- W4230865099 via openalex
- W4254652493 via openalex
- W4255182111 via openalex
- W6628620898 via openalex
- W6670968058 via openalex
- W6675215966 via openalex
- W2246590518 via openalex
- W156899246 via openalex
- W1481592502 via openalex
- W1908603549 via openalex
- W1910306760 via openalex
- W1928861982 via openalex
- W1963831711 via openalex
- W1970539961 via openalex
- W1973759771 via openalex
Cited by (3)
- Hormonal therapy for endometriosis: from molecular research to bedside 2016
- Abnormal excessive per vagina (PV) bleeding on Esmya–selective progesterone receptor modulator (SPRM) in a symptomatic patient with uterine fibroid 2015
- Uterine Leiomyomas: Effects on Architectural, Cellular, and Molecular Determinants of Endometrial Receptivity 2012
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00